Antiatheromatic effects of insulin

Diabetes Research and Clinical Practice

Volumn 93, Issue SUPPL. 1, 2011, Pages

  Karamitsos, Dimitrios T ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Atherosclerosis; Cardioprotection; Fibrinolysis; Low grade inflammation; Platelets

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; INSULIN; POTASSIUM; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTERY DILATATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG EFFECT; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTERSTITIAL PNEUMONIA; LIPOLYSIS; LIVER PROTECTION; NONHUMAN; TREATMENT DURATION; VASODILATATION;

ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; VASODILATION;

EID: 84860417839     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/S0168-8227(11)70024-9     Document Type: Article

References (31)

1. Orchard TJ, Becker DJ, Bates M Plasma insulin and lipoprotein concentrations: an atherogenic association?. Am J Epidemiol 1983, 118:326-337.
2. Pyörälä K, Laakso M, Uusitupa M Diabetes and atherosclerosis: an epidemiologic view. Diabetes/metabolism reviews 1987, 3:463-524.
3. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991, 34:356-361.
4. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischémie heart disease. N Engl J Med 1996, 334:952-957.
5. Stout RW Insulin and atheroma. Diabetes Care 1990, 13:631-654.
6. Dandona P, Aijada A, Dhindsa S, Garg R Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone 2003, (Suppl 4):S13-S20.
7. Davies MJ, Metcalfe J, Gray IP, Day JL, Hales CN Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993, 10:305-312.
8. Nesher R, Delia Casa L, Litvin Y, et al. Insulin deficiency and insulin resistance in type 2 diabetes: Quantitative contributions of pancreatic and periferal responses to glucose homeostasis. Eur J Clin Invest 1987, 17:266-274.
9. Jarrett RG Is insulin atherogenic. Diabetologia 1988, 31:71-75.
10. Wingard DL, Barret-Connor EL, Ferrara A Is insulin really a heart disease risk factor?. Diabetes Care 1995, 18:1299-1304.
11. Durrington PN Is insulin atherogenic?. Diabet Med 1992, 9:597-600.
12. Dandona P, Aijada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S Insulin inhibits intranuclear NFKB and stimulates IkB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 2001, 86:3257-3265.
13. Graver A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension 1995, 25:779-784.
14. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P Nitricoxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994, 94:2511-2515.
15. Riddel DR, Owen JS Nitric oxide and platelet aggregation. Vitam Horm 1999, 57:25-48.
16. Mavridis G, Souliou E, Diza E, et al. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2008, 18:471-476.
17. Ghanim H, Mohandy P, Deopukar R, et al. Acute modulation of toll-like receptors by insulin. Diabetes Care 2008, 31:1827-1831.
18. Jonassen AK, Brar BK, Mjos OD, et al. Insulin administered at reoxygenation exerts a cardioprotective effect in monocytes by a possible antiapoptotic mechanism. J Mol Cell Cardiol 2000, 32:757-764.
19. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002, 105:1497-1502.
20. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991, 65:130-133.
21. Zhang HX, Zang YM, Huo JH, et al. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharmacol 2006, 48:306-313.
22. Chaudhuri A, Janicke D, Wilson M, et al. Effect of modified glucose-insulin-potassium on free fatty acids, matrix metalloproteinase, and myoglobin in ST-elevation myocardial infarction. Am J Cardiol 2007, 100:1614-1618.
23. Worthley MI, Holmes AS, Willoughby SR, et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by Superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 2007, 49:304-310.
24. Malmberg K Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314:1512-1515.
25. Malmberg K, Rydén L, Wedel H, et al. DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650-661.
26. CREATE-ECLA Trial Group Investigators Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. The CREATE-ECLA randomized controlled trial. JAMA 2005, 293:437-446.
27. Nathan DM, Cleary PA, Baclund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005, 353:2643-2653.
28. Dandona P, Chaudhuri A, Ghanim H, Mohanty P Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009, 53(Suppl 5):S14-S20.
29. Kim T, Chan KK, Dhaliwall JK, et al. Anti-atherogenic effect of insulin in vivo. J Vase Res 2005, 42:455-462.
30. Cersosimo E, DeFronzo RA Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423-436.
31. Amar J, Perez L, Burcelin R, Chamontin B Arteries, inflammation and insulin resistance. J Hypertens Suppl 2006, 24:S18-S20.